Last reviewed · How we verify
SP Shz TIV
SP Shz TIV is a trivalent inactivated influenza vaccine that stimulates immune responses against three seasonal influenza virus strains.
SP Shz TIV is a trivalent inactivated influenza vaccine that stimulates immune responses against three seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | SP Shz TIV |
|---|---|
| Also known as | Sanofi Pasteur Shenzhen Trivalent Influenza Vaccine |
| Sponsor | Sanofi |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This vaccine contains inactivated (killed) influenza virus antigens representing three circulating strains (typically two A subtypes and one B lineage). It works by presenting these antigens to the immune system to generate both humoral (antibody) and cellular immune responses, providing protection against infection by matching strains during the influenza season.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fever
- Fatigue
Key clinical trials
- Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age (PHASE3)
- Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years (PHASE4)
- Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SP Shz TIV CI brief — competitive landscape report
- SP Shz TIV updates RSS · CI watch RSS
- Sanofi portfolio CI